

■ CDH16 MSVA-516R weak (%) ■ CDH16 MSVA-516R moderate (%) ■ CDH16 MSVA-516R strong (%)

% of tumors

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0



* Includes Type and Type 2 pRCC, 144 pRCC lack information on type.